GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife’s subsidiary Xvivo, with business activities within the organ transplant area, is in an intensive and exciting development phase which now requires greater focus, and will thus become a more independent unit within the Vitrolife Group. Vitrolife’s former CEO Magnus Nilsson will, as the CEO of Xvivo, be able to focus entirely on this line of business. The Board intends to propose to the shareholders that Magnus be given the opportunity to buy into the company and become the owner of approximately 15% of Xvivo. Xvivo will also have an external Board.
